Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2010 | Focus on

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

Authors: Massimo Salvatori, Markus Luster

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2010

Excerpt

“Treatments with radioiodine should be based on principles leading to the highest quality of patient care. Science is the basis for the principles and for the advances we seek in medicine” [ 1 ]. (James Sisson)

…

Sisson JC, Avram AM, Rubello D, Gross MD. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging 2007;34(7):1129–30.CrossRefPubMed

Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJG, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34(5):772–86.CrossRefPubMed

Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray” [letter to the editor]. Eur J Nucl Med Mol Imaging 2007;34(10):1699–700.CrossRefPubMed

Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? J Nucl Med 1993;34(10):1638–41.PubMed

de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009;161(5):771–7.CrossRefPubMed

Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun 2009;30(2):169–75.CrossRefPubMed

Walter MA, Schindler C, Christ-Crain M, Müller-Brand J, Müller B. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models. Eur J Clin Invest 2009;39(1):51–7.CrossRefPubMed

Traino A, Xhafa B. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves’ disease. Med Phys 2009;36(4):1212–8.CrossRefPubMed

Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun 2010;31:201–5.CrossRefPubMed

10.

Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, et al. Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun 2009;30(6):466–71.CrossRefPubMed

11.

Fast S, Nielsen VE, Bonnema SJ, Hegedüs L. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 2009;160(4):517–28.CrossRefPubMed

12.

Braverman L, Kloos RT, Law Jr B, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract 2008;14(7):832–9.PubMed

13.

Cubas ER, Paz-Filho GJ, Olandoski M, Goedert CA, Woellner LC, Carvalho GA, et al. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int J Clin Pract 2009;63(4):583–90.CrossRefPubMed

14.

Sisson JC, Dewaraja YK, Wizauer EJ, Giordano TJ, Avram AM. Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. Thyroid 2009;19(3):297–303.CrossRefPubMed

15.

De Klerk JM, Oyen WJ. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases. Minerva Endocrinol 2009;34(1):57–69.PubMed

16.

Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35(7):1405–12.CrossRefPubMed

17.

Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging; 2009 Dec 24. [Epub ahead of print] doi:10.1007/s00259-009-1303-x.

18.

Stahl AR, Freudenberg L, Bockisch A, Jentzen W. A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36(7):1147–55.CrossRefPubMed

19.

Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:270–5. 2009 Sep 4. [Epub ahead of print] doi:10.1007/s00259-009-1261-3.

20.

Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2009;16(4):1283–9.CrossRefPubMed

21.

Capoccetti F, Criscuoli B, Rossi G, Ferretti F, Manni C, Brianzoni E. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009;53(5):536–45.PubMed

22.

Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp Clin Endocrinol Diabetes; 2009. [Epub ahead of print] doi:10.1055/s-0029-1225350.

23.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008;49(6):1017–23.CrossRefPubMed

24.

Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, et al. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med 2009;50(11):1844–7.CrossRefPubMed

Title: Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma
Authors: Massimo Salvatori
Markus Luster
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1398-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2010

68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours

Highlights of the EANM Congress Barcelona 2009: increasing our impact in diagnostic imaging

Erratum to: Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm

Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm

Darwinian molecular imaging in nuclear cardiology

PET/CT colonography: a novel non-invasive technique for assessment of extent and activity of ulcerative colitis